Clinical Trial Update: Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab [Phase 3]

View source ↗

Summary

Phase 3 trial investigating rechallenge with pyro tinib in HER2-positive metastatic breast cancer previously treated with pyrotinib and trastuzumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: Fudan University | Conditions: HER2-positive Breast Cancer, Metastatic Breast Cancer | Phase 3 | Status: UNKNOWN